This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Arch Ophthalmol. 2004;122:928-930.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Isotretinoin and etretinate are synthetic retinoids commonly used to treat skin disorders. Ocular adverse effects have been reported after short- and long-term use of these drugs,^1-4 with keratoconjuctivitis sicca¹ being the most common one.

Nictalopia and decreased dark adaptation have been described in patients treated with isotretinoin² and etretinate.³ Furthermore, abnormalities in the electroretinogram (ERG), including reduced scotopic amplitudes^{1, 3} and color vision,³ have also been reported.

The case of a 32-year-old man who noted decreased visual acuity (VA) after long-term use of acitretin (Neotigason), a metabolite of etretinate, is reported. Slitlamp biomicroscopy, fluorescein angiography (FFA), and electrophysiology findings are described.

Report of a Case

A 32-year-old white man was seen in the emergency department on July 26, 2002, reporting a 3-day history of blurred vision in both eyes. His medical history was remarkable for previous hepatitis B infection and severe psoriasis for which he had been treated with acitretin, 30 mg/d, for the past . . . [Full Text of this Article]

Comment
Noemi Lois, MD, PhD; Marion White, FRCP
Aberdeen, Scotland

Corresponding author: Noemi Lois, MD, PhD, Retina Service, Ophthalmology Department, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZN, Scotland (e-mail: noemilois@aol.com).